<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Acid suppression is the mainstay of therapy in <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">gastro-oesophageal reflux disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="50275">Esomeprazole</z:chebi> 40 mg is more effective than <z:chebi fb="0" ids="6375">lansoprazole</z:chebi> 30 mg in healing mucosal lesions in severe erosive <z:e sem="disease" ids="C0677659,C0014869" disease_type="Disease or Syndrome" abbrv="">reflux oesophagitis</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>However, data comparing <z:chebi fb="0" ids="50275">esomeprazole</z:chebi> with <z:chebi fb="0" ids="6375">lansoprazole</z:chebi> in patients with complications of <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">gastro-oesophageal reflux disease</z:e>, such as ulcerative <z:e sem="disease" ids="C0677659,C0014869" disease_type="Disease or Syndrome" abbrv="">reflux oesophagitis</z:e> and <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e>, are lacking </plain></SENT>
<SENT sid="3" pm="."><plain>AIM: To compare the efficacy of <z:chebi fb="0" ids="50275">esomeprazole</z:chebi> and <z:chebi fb="0" ids="6375">lansoprazole</z:chebi> at their standard dosages in suppressing oesophageal acid exposure in complicated <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">gastro-oesophageal reflux disease</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Thirty patients with complicated <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">gastro-oesophageal reflux disease</z:e> (7 with ulcerative <z:e sem="disease" ids="C0677659,C0014869" disease_type="Disease or Syndrome" abbrv="">reflux oesophagitis</z:e> and 23 with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e>), randomly assigned to receive 40 mg <z:chebi fb="0" ids="50275">esomeprazole</z:chebi> (n=16) or 30 mg <z:chebi fb="0" ids="6375">lansoprazole</z:chebi> (n=14) once daily, underwent oesophageal 24-h pH monitoring while on therapy </plain></SENT>
<SENT sid="5" pm="."><plain>Total, upright diurnal and supine nocturnal percentage <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">acid reflux</z:e> time were assessed </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: <z:chebi fb="0" ids="50275">Esomeprazole</z:chebi> was significantly more effective than <z:chebi fb="0" ids="6375">lansoprazole</z:chebi> in decreasing oesophageal acid exposure </plain></SENT>
<SENT sid="7" pm="."><plain>Normalisation of both total and supine nocturnal percentage <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">acid reflux</z:e> time was obtained in 12 of 16 (75%) patients treated with <z:chebi fb="0" ids="50275">esomeprazole</z:chebi> but only in 4 of 14 (28%) cases treated with <z:chebi fb="0" ids="6375">lansoprazole</z:chebi> (p=0.026) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Normalisation of oesophageal acid exposure can be achieved in the majority of complicated <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">gastro-oesophageal reflux disease</z:e> cases with <z:chebi fb="0" ids="50275">esomeprazole</z:chebi> 40 mg once daily </plain></SENT>
</text></document>